• HSP27 Expression as a Novel Predictive Biomarker for Bevacizumab: is it Cost Effective? 

      Seo, Mikyung Kelly; Straume, Oddbjørn; Akslen, Lars A.; Cairns, John Alexander (Journal article; Peer reviewed, 2020)
      Background: Despite the extensive use of bevacizumab in a range of oncology indications, the US FDA revoked its approval for breast cancers, and multiple negative trials in several solid malignancies have been reported, ...